Almouzain, L;
Stevenson, F;
Chard, D;
Rahman, NA;
Hamilton, F;
(2021)
Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy.
Multiple Sclerosis Journal - Experimental, Translational and Clinical
, 7
(1)
10.1177/20552173211001571.
Preview |
Text
Chard_Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy_VoR.pdf - Published Version Download (574kB) | Preview |
Abstract
Background: The decision to have children can be complex, particularly for people with multiple sclerosis (MS). A key concern is the use of disease modifying drugs (DMDs) during pregnancy, and how continuing, stopping or switching them may affect the mother and child. In people with active MS, stopping medications puts the mother at risk of relapse and disease rebound. Objectives: Review evidence on the effect of different switching strategies in people with stable relapsing remitting MS (RRMS). Methods: We searched MEDLINE, EMBASE, EMCARE, CINAHL, SCOPUS, Cochrane Library up to March 2020. Only papers in English were included and no other limits were applied. Seven articles were included: four cohorts, two case reports and one randomized controlled trial (RCT). Results: Two strategies were found: de-escalating, which was associated with an increased risk of relapses, and switching between first line injectables, with no change in relapse rate observed. Conclusion: Evidence on the effect of switching strategy on disease course in stable RRMS patients planning for pregnancy is scarce, but when switching, current evidence suggests the risk of relapses mirrors known medication efficacy.
| Type: | Article |
|---|---|
| Title: | Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/20552173211001571 |
| Publisher version: | http://dx.doi.org/10.1177/20552173211001571 |
| Language: | English |
| Additional information: | https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| Keywords: | Multiple sclerosis, relapsing-remitting, substitute, switch, interferons, glatiramer acetate |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Primary Care and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10125433 |
Archive Staff Only
 |
View Item |
